Fibrocalcific phenotypes in calcific aortic valve disease: imaging characterization, treatment timing, and efficacy assessment
- 1First Clinical Medical College, Gannan Medical University
- 2Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University
- 3Cardiology Medical Center, First Affiliated Hospital of Gannan Medical University, Gannan Medical University
Abstract
Calcific aortic valve disease involves two structural processes, fibrous matrix remodeling and mineral deposition, that contribute unequally between patients, so leaflets of similar hemodynamic severity need not share the same tissue composition. Histologic and multi-omics studies have mapped this heterogeneity across sex, age, and valve morphology, and contrast-enhanced computed tomography angiography (CTA) has brought compositional assessment into living patients and into longitudinal follow-up. Calcific burden behaves consistently: it tracks stenosis severity, predicts progression, and carries prognostic weight. Findings for noncalcified tissue are less settled and depend on the population studied and on how the measurement is made. Whether total fibrocalcific volume performs well as a structural endpoint and whether CTA-derived noncalcified tissue volume adds predictive value beyond calcification are consequently two separate questions, and the literature often merges them. Pharmacologic trials in patients have almost always measured calcification progression or hemodynamics rather than longitudinal change in the fibrous matrix. Randomized lipid-lowering and mineral-targeted trials in patients have been negative, whereas animal and cell experiments show that established mineral lesions, cell states, and function can sometimes be modified, although these responses do not necessarily move together. This review integrates histology, multimodality imaging, clinical cohorts, pharmacologic trials, and preclinical intervention studies to define the fibrocalcific phenotype, distinguish prevention from slowing and reversal, and align therapeutic timing with endpoints at the levels of activity, tissue burden, valve function, myocardial response, and clinical events. Longitudinal measurement of leaflet composition and validation of treatment-induced change against functional outcomes remain the central gaps.
Related
- Quantitative MRI Characterization of Fluid-Related Phenotypes in Pediatric Epilepsy: Deep Learning-Assisted Assessment of Enlarged Perivascular Space Burden, Regional Distribution, and Clinical Associations
- Single-cell characterization of 3D CLL spheroid model that recapitulates lymph node microenvironment-driven phenotypes and in vivo drug responses to ibrutinib
- iPSC-Derived T and CAR-T Cells of Distinct Phenotypes: Current Protocols, Challenges and Potential for Cancer Treatment
- Body Composition Phenotypes and Their Metabolic Associations in Treatment-Naïve Patients With Newly Diagnosed Type 2 Diabetes: A DXA-Based Cluster Analysis.
- Peripheral immune biomarkers, brain imaging phenotypes and treatment response in major depressive disorder
BibTeX
@article{liu2026fibrocalcific,
title = {{Fibrocalcific phenotypes in calcific aortic valve disease: imaging characterization, treatment timing, and efficacy assessment}},
author = {Feng Liu and Zhaohong Zeng and Zhian Qian and Wentong Li and Yuting Huang and Ziyou Liu},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1997440},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1997440/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fibrocalcific phenotypes in calcific aortic valve disease: imaging characterization, treatment timing, and efficacy assessment
AU - Feng Liu
AU - Zhaohong Zeng
AU - Zhian Qian
AU - Wentong Li
AU - Yuting Huang
AU - Ziyou Liu
PY - 2026
DA - 2026/10/27
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1997440
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1997440/full
AB - Calcific aortic valve disease involves two structural processes, fibrous matrix remodeling and mineral deposition, that contribute unequally between patients, so leaflets of similar hemodynamic severity need not share the same tissue composition. Histologic and multi-omics studies have mapped this heterogeneity across sex, age, and valve morphology, and contrast-enhanced computed tomography angiography (CTA) has brought compositional assessment into living patients and into longitudinal follow-up. Calcific burden behaves consistently: it tracks stenosis severity, predicts progression, and carries prognostic weight. Findings for noncalcified tissue are less settled and depend on the population studied and on how the measurement is made. Whether total fibrocalcific volume performs well as a structural endpoint and whether CTA-derived noncalcified tissue volume adds predictive value beyond calcification are consequently two separate questions, and the literature often merges them. Pharmacologic trials in patients have almost always measured calcification progression or hemodynamics rather than longitudinal change in the fibrous matrix. Randomized lipid-lowering and mineral-targeted trials in patients have been negative, whereas animal and cell experiments show that established mineral lesions, cell states, and function can sometimes be modified, although these responses do not necessarily move together. This review integrates histology, multimodality imaging, clinical cohorts, pharmacologic trials, and preclinical intervention studies to define the fibrocalcific phenotype, distinguish prevention from slowing and reversal, and align therapeutic timing with endpoints at the levels of activity, tissue burden, valve function, myocardial response, and clinical events. Longitudinal measurement of leaflet composition and validation of treatment-induced change against functional outcomes remain the central gaps.
SN - 2297-055X
ER -